254 related articles for article (PubMed ID: 18078622)
1. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
[TBL] [Abstract][Full Text] [Related]
2. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
3. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
4. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
7. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
[TBL] [Abstract][Full Text] [Related]
8. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
11. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
[TBL] [Abstract][Full Text] [Related]
12. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease.
Tiev KP; Rivière S; Hua-Huy T; Cabane J; Dinh-Xuan AT
Nitric Oxide; 2014 Aug; 40():17-21. PubMed ID: 24831352
[TBL] [Abstract][Full Text] [Related]
13. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.
Domiciano DS; Bonfá E; Borges CT; Kairalla RA; Capelozzi VL; Parra E; Christmann RB
Clin Rheumatol; 2011 Feb; 30(2):223-9. PubMed ID: 20544245
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
16. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
17. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
18. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
[TBL] [Abstract][Full Text] [Related]
19. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
Roth MD; Tseng CH; Clements PJ; Furst DE; Tashkin DP; Goldin JG; Khanna D; Kleerup EC; Li N; Elashoff D; Elashoff RM;
Arthritis Rheum; 2011 Sep; 63(9):2797-808. PubMed ID: 21547897
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
